Maroteaux-Lamy Syndrome Clinical Trial
Official title:
Study of Administration of Intravenous Naglazyme® Following Allogeneic Transplantation for Maroteaux-Lamy Syndrome
This is a single center study in which Naglazyme® will be given weekly for two years in patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who have previously been treated with an allogeneic transplant.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00299000 -
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
|
Phase 4 | |
Terminated |
NCT00668564 -
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
|
Phase 2 | |
Completed |
NCT01043640 -
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
|
Phase 2 |